/PRNewswire/ Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining.
– FokusRx™ feasibility study demonstrates positive results – – Company plans to initiate Phase 3 trial with FokusRx in ADHD in the second half of 2022 –.
/PRNewswire/ Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining.